News | January 26, 2022
Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
UCB plans to submit regulatory applications in Q3 2022
However, these won’t be available at the nearest chemist store soon
Ram’s appointment follows the launch of the CDI India division in October 2021.
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
Subscribe To Our Newsletter & Stay Updated
